ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 219 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q3 2023. The put-call ratio across all filers is 0.74 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,030 | -70.1% | 85 | -61.4% | 0.00% | -100.0% |
| Q2 2023 | $10,149 | +31.8% | 220 | +14.6% | 0.00% | 0.0% |
| Q1 2023 | $7,699 | -62.2% | 192 | -56.4% | 0.00% | -66.7% |
| Q4 2022 | $20,385 | +307.7% | 440 | +286.0% | 0.00% | +200.0% |
| Q3 2022 | $5,000 | +150.0% | 114 | +307.1% | 0.00% | – |
| Q1 2022 | $2,000 | 0.0% | 28 | +16.7% | 0.00% | – |
| Q4 2021 | $2,000 | +100.0% | 24 | +242.9% | 0.00% | – |
| Q1 2021 | $1,000 | 0.0% | 7 | -58.8% | 0.00% | – |
| Q4 2019 | $1,000 | -75.0% | 17 | -80.5% | 0.00% | -100.0% |
| Q3 2019 | $4,000 | 0.0% | 87 | +38.1% | 0.00% | 0.0% |
| Q2 2019 | $4,000 | 0.0% | 63 | 0.0% | 0.00% | 0.0% |
| Q1 2019 | $4,000 | +100.0% | 63 | 0.0% | 0.00% | +100.0% |
| Q4 2018 | $2,000 | – | 63 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| First Light Asset Management, LLC | 213,887 | $29,608,000 | 2.19% |
| Rock Springs Capital Management LP | 566,500 | $78,421,000 | 1.66% |
| FEDERATED HERMES, INC. | 4,280,528 | $592,554,000 | 1.21% |
| AtonRa Partners | 17,646 | $2,443,000 | 1.20% |
| EMERALD MUTUAL FUND ADVISERS TRUST | 218,390 | $30,232,000 | 1.05% |
| EMERALD ADVISERS, LLC | 226,875 | $31,406,000 | 1.04% |
| Atika Capital Management LLC | 89,000 | $12,319,000 | 0.96% |
| Capital Impact Advisors, LLC | 25,582 | $3,541,000 | 0.87% |
| JGP Global Gestao de Recursos Ltda. | 1,586 | $220,000 | 0.83% |
| CAPITAL INTERNATIONAL LTD /CA/ | 79,742 | $11,039,000 | 0.64% |